EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?

Nicolas Johner iD, Baris Gencer iD, Marco Roffi iD

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Nicolas Johner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Geneva University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Beta‐blocker therapy, a treatment burdened by side effects including fatigue, erectile dysfunction and depression, was shown to reduce mortality and cardiovascular events after acute coronary syndromes (ACS) in the pre‐coronary reperfusion era. Potential mechanisms include protection from ventricular arrhythmias, increased ischaemia threshold and prevention of left ventricular (LV) adverse remodelling. With the advent of early mechanical reperfusion and contemporary pharmacologic secondary prevention, the benefit of beta‐blockers after ACS in the absence of LV dysfunction has been challenged.

Methods

The present narrative review discusses the contemporary evidence based on searching the PubMed database and references in identified articles.

Results

Recently, the REDUCE‐AMI trial—the first adequately powered randomized trial in the reperfusion era to test beta‐blocker therapy after myocardial infarction with preserved left ventricular ejection fraction (LVEF)—showed no benefit on the composite of all‐cause death or myocardial infarction over a median 3.5‐year follow‐up. While the benefit of beta‐blockers in patients with reduced LVEF remains undisputed, their value in post‐ACS patients with mildly reduced systolic function (LVEF 41%–49%) has not been studied in contemporary randomized trials; in this setting, observational studies have suggested a reduction in cardiovascular events with these agents. The adequate duration of beta‐blocker therapy remains unknown, but observational data suggests that any mortality benefit may be lost beyond 1–12 months after ACS in patients with LVEF >40%.

Conclusion

We believe that there is sufficient evidence to abandon routine beta‐blocker prescription in post‐ACS patients with preserved LV systolic function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAdrenergic beta-AntagonistsHumansMyocardial InfarctionRandomized Controlled Trials as TopicSecondary PreventionStroke Volume

Stichwörter der Autor:innen

NSTEMISTEMIacute coronary syndromebeta‐blockermyocardial infarctionpreserved ejection fraction

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
  • Institute of Primary Healthcare (BIHAM), University of Bern, Bern, Switzerland.
  • Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.

ORCID-Profile: Nicolas Johner, Baris Gencer, Marco Roffi

Zitieren

APA

Johner, N., Gencer, B., & Roffi, M. (2024). Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14309

Vancouver

Johner N, Gencer B, Roffi M. Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14309

BibTeX
@article{Johner2024,
  author = {Johner, Nicolas and Gencer, Baris and Roffi, Marco},
  title = {Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14309}
}
Kostenlos starten →